OntologiesCurators at RGD make annotations to genes, QTLs and strains using standardized vocabularies/ontologies. Your search returned annotations to the terms below.ChEBI: ChEBI Ontology
11a-hydroxytigecycline(1+)
14-F2-dihomo-IsoP
20:2(5Z,9Z)(11Me,15Me,19Me)
5'-GAAACAC-3' RNA fragment
[1-[3-(4-fluorophenoxy)propyl]-4-piperidinyl]-diphenylmethanol
almazole C
CID 91860896
Condurango glycoside A
DG(18:1(11Z)/20:3(8Z,11Z,14Z)/0:0)
Gly-Ala-Ala
Gly-L-Ala-L-Ala-D-Ala-D-Ala
Gly-Pro-Lys
LY-165163
methylnaltrexone
Mirabilene A isonitrile
N-[(2R,3R,4R,5S,6R)-2-[[(2R,3R,4R,5R)-5-Acetamido-4-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,6-dihydroxyoxan-2-yl]methoxy]-5-[(2S,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
N-[(2R,3R,4R,5S,6R)-2-[[(2R,3R,4R,5R,6S)-5-Acetamido-4-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,6-dihydroxyoxan-2-yl]methoxy]-5-[(2S,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
N-[(3R,4R,5S,6R)-5-[(2S,3S,4S,5R,6R)-4-[(2R,3S,4S,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2S,3S,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
N-[(3R,4R,5S,6R)-5-[(2S,3S,4S,5R,6R)-6-[[(2S,3S,4S,5R,6R)-4-[(2R,3S,4S,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,5-dihydroxy-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
poly[d(GAA)]
poly[d(TTC)].poly[d(GAA)]
Recombinant Tumor Necrosis Factor TNF alpha (Zebrafish)
S. flexneri serotype 1b O-polysaccharide (O factor 9-positive)
EFO: Experimental Factor Ontology
GAA (human)
Gaaliin
glycogen storage disease II
GM15850
GM15851
lysosomal alpha-glucosidase
lysosomal alpha-glucosidase (human)
lysosomal alpha-glucosidase proteolytic cleavage product
nucleoside diphosphate kinase A
GO: Biological Process
cellular response to amino acid starvation
GO: Cellular Component
GPI-anchor transamidase complex
GO: Molecular Function
alpha-glucosidase activity
GAA codon-amino acid adaptor activity
HP: Human Phenotype
Decreased circulating guanidinoacetic acid concentration
Decreased CSF guanidinoacetic acid concentration
PW: Pathway Ontology
glycogen storage disease type II pathway
RDO: RGD Disease Ontology
Friedreich ataxia
glycogen storage disease II
Pompe disease, infantile-onset
Pompe disease, late-onset
spinocerebellar ataxia 27B
SO: Sequence Ontology
glutamic_acid
NDM3_motif
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||



















